Astal Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2025 ,inter alia, to consider and approve Submission of prior intimation ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astal Laboratories Ltd (formerly Macro International Limited) has called a Board meeting on 12 August 2025 with a packed agenda. Key items include approval of unaudited standalone Q1 FY26 (quarter ended 30 June 2025) financial results and the 32nd Annual General Meeting notice along with the Board Report for FY25. The Board will also consider allotment of equity shares on conversion of warrants issued earlier on a preferential basis. Notably, the Board will discuss an initial investment proposal to acquire 100% equity of Sriven Pharmachem India Private Limited (SPIPL), subject to valuation and due diligence. Several housekeeping items seek shareholder approval later — raising borrowing limits under Section 180(1)(c), creating charges on assets under Section 180(1)(a), and increasing limits for investments/loans under Sections 186 and 185. The trading window for insiders is already closed from 1 July 2025 until 48 hours after the Board meeting concludes.
Q1 results and the possible acquisition of SPIPL are the most stock-moving items to watch on 12 August. The proposed preferential warrant conversion and higher borrowing limits signal potential equity dilution and increased leverage, pending shareholder approval.